Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas

Oncogene

Volumn 26, Issue 53, 2007, Pages 7401-7413

  Sugino, Y ^a,b,c   Misawa, A ^a,b   Inoue, J ^a,b   Kitagawa, M ^a   Hosoi, H ^c   Sugimoto, T ^c   Imoto, I ^a,b   Inazawa, J ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

cAMP; DNA methylation; Histone modification; Neuroblastoma; PTGER2; Tumor suppressor

Indexed keywords

8 BROMO CYCLIC AMP; BUTAPROST; CYCLIC AMP; HISTONE H3; HISTONE H4; LYSINE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT;

APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DEACETYLATION; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; TUMOR GROWTH;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ALPROSTADIL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DINOPROSTONE; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEUROBLASTOMA; PROMOTER REGIONS (GENETICS); RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER;

BACTERIA (MICROORGANISMS);

EID: 36349009317     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210550     Document Type: Article

References (44)

1. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y et al. (2005). CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65: 828-834.
2. Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM et al. (2006). Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8: 532-538.
3. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. (1993). Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477.
4. Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
5. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. (2005). Prostaglandin E2 promotes colon cancer cell growth through a GS-axin-beta-catenin signaling axis. Science 310: 1504-1510.
6. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. (1998). Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 78: 165-174.
7. del Carmen Mejia M, Navarro S, Pellin A, Ruiz A, Castel V, Llombart-Bosch A. (2002). Study of proliferation and apoptosis in neuroblastoma. Their relation with other prognostic factors. Arch Med Res 33: 466-472.
8. Fedyk ER, Ripper JM, Brown DM, Phipps RP. (1996). A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: coexpression of EP1, EP2, EP3beta and EP4. Mol Immunol 33: 33-45.
9. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. (2006). Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38: 540-549.
10. Fulton AM, Laterra JJ, Hanchin CM. (1989). Prostaglandin E2 receptor heterogeneity and dysfunction in mammary tumor cells. J Cell Physiol 139: 93-99.
11. Hata AN, Breyer RM. (2004). Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147-166.
12. Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, Mizushima T. (2003). Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 278: 12752-12758.
13. Inazawa J, Inoue J, Imoto I. (2004). Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 95: 559-563.
14. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A et al. (2004). Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64: 7210-7215.
15. Jones PA, Baylin SB. (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
16. Kondo Y, Shen L, Issa JP. (2003). Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23: 206-215.
17. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. (2004). Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 11: 1068-1075.
18. Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F et al. (2005). Methylation-associated silencing of the Nuclear Receptor 1I2 gene in advanced-type Neuroblastomas, Identified by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification. Cancer Res 65: 10233-10242.
19. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y et al. (2003). Silencing effect of CpG island hypermethylation and histone modifications on O6-methyl-guanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22: 8835-8844.
20. Narumiya S, Sugimoto Y, Ushikubi F. (1999). Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226.
21. Okuyama T, Ishihara S, Sato H, Rumi MA, Kawashima K, Miyaoka Y et al. (2002). Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. J Lab Clin Med 140: 92-102.
22. Regan JW. (2003). EP2 and EP4 prostanoid receptor signaling. Life Sci 74: 143-153.
23. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto S et al. (2003). PPM1D Is a Potential Target for 17q Gain in Neuroblastoma. Cancer Res 63: 1876-1883.
24. Santoro MG, Philpott GW, Jaffe BM. (1977). Inhibition of B-16 melanoma growth in vivo by a synthetic analog of prostaglandin E2. Cancer Res 37: 3774-3779.
25. Schubeler D, Lorincz MC, Cimbora DM, Telling A, Feng YQ, Bouhassira EE et al. (2000). Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol Cell Biol 20: 9103-9112.
26. Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K et al. (2004). Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res 64: 3741-3747.
27. Stirzaker C, Song JZ, Davidson B, Clark SJ. (2004). Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 64: 3871-3877.
28. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. (2005). Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 25: 3923-3933.
29. Suda M, Tanaka K, Natsui T, Usui T, Tanaka I, Fukushima M et al. (1996). Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 137: 1698-1705.
30. Takadera T, Shiraishi Y, Ohyashiki T. (2004). Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int 45: 713-719.
31. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535.
32. Thompson PM, Seigfried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM et al. (2001). Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol 36: 28-31.
33. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M et al. (1999). Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59: 2307-2312.
34. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. (2005a). Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65: 1822-1829.
35. Wang D, DuBois RN. (2006). Prostaglandins and cancer. Gut 55: 115-122.
36. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q et al (2006). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941-951.
37. Wang HM, Zheng NG, Wu JL, Gong CC, Wang YL. (2005b). Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol 11: 6538-6542.
38. Westermann F, Schwab M. (2002). Genetic parameters of neuroblastomas. Cancer Lett 184: 127-147.
39. Wolffe AP, Matzke MA. (1999). Epigenetics: regulation through repression. Science 286: 481-486.
40. Xiong Z, Laird PW. (1997). COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534.
41. Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M et al. (2006). MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 119: 1850-1857.
42. Yan P, Muhlethaler A, Bourloud KB, Beck MN, Gross N. (2003). Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Gene Chromosome Cancer 36: 129-138.
43. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR et al. (2004). Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 10: 8493-8500.
44. Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J et al. (2003). Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 63: 6299-6310.